Celltrion sees market share of Remsima rising in European nations
SEOUL, Celltrion Inc. saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday.
The combined market share of Remsima and the subcutaneous …